KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case–Control Study

References

• Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–558. doi:10.1136/ard.61.6.554
   PubMed Web of Science ®Google Scholar
• Palm O, Garen T, Berge Enger T, et al. Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality–a retrospective study based on registry data. Rheumatology. 2013;52(1):173–179. doi:10.1093/rheumatology/kes311
   PubMed Web of Science ®Google Scholar
• Uffmann M, Kiener HP, Bankier AA, Baldt MM, Zontsich T, Herold CJ. Lung manifestation in asymptomatic patients with primary Sjogren syndrome: assessment with high resolution CT and pulmonary function tests. J Thorac Imaging. 2001;16(4):282–289. doi:10.1097/00005382-200110000-00009
   PubMed Web of Science ®Google Scholar
• Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol. 1988;18(3):203–216.
   PubMed Web of Science ®Google Scholar
• Oyama T, Kohno N, Yokoyama A, et al. Detection of interstitial pneumonitis in patients with rheumatoid arthritis by measuring circulating levels of KL-6, a human MUC1 mucin. Lung. 1997;175(6):379–385. doi:10.1007/PL00007584
   PubMed Web of Science ®Google Scholar
• Castro I, Albornoz N, Aguilera S, et al. Aberrant MUC1 accumulation in salivary glands of Sjogren’s syndrome patients is reversed by TUDCA in vitro. Rheumatology. 2020;59(4):742–753. doi:10.1093/rheumatology/kez316
   PubMed Web of Science ®Google Scholar
• Kohno N. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis. J Med Invest. 1999;46(3–4):151–158.
   PubMedGoogle Scholar
• Hirasawa Y, Kohno N, Yokoyama A, Inoue Y, Abe M, Hiwada K. KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts. Am J Respir Cell Mol Biol. 1997;17(4):501–507. doi:10.1165/ajrcmb.17.4.2253
   PubMed Web of Science ®Google Scholar
• Li X, Xu B, Ma Y, et al. Clinical and laboratory profiles of primary Sjogren’s syndrome in a Chinese population: a retrospective analysis of 315 patients. Int J Rheum Dis. 2015;18(4):439–446. doi:10.1111/1756-185X.12583
   PubMed Web of Science ®Google Scholar
• Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper. Lancet Respir Med. 2018;6(2):138–153. doi:10.1016/S2213-2600(17)30433-2
   PubMed Web of Science ®Google Scholar
• Heinze G, Wallisch C, Dunkler D. Variable selection - A review and recommendations for the practicing statistician. Biom J. 2018;60(3):431–449. doi:10.1002/bimj.201700067
   PubMed Web of Science ®Google Scholar
• Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Akiyama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest. 1989;96(1):68–73. doi:10.1378/chest.96.1.68
   PubMed Web of Science ®Google Scholar
• Hamada H, Kohno N, Akiyama M, Hiwada K. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia. Chest. 1992;101(3):858–860. doi:10.1378/chest.101.3.858
   PubMed Web of Science ®Google Scholar
• Kohno N, Hamada H, Fujioka S, Hiwada K, Yamakido M, Akiyama M. Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer. Chest. 1992;102(1):117–122. doi:10.1378/chest.102.1.117
   PubMed Web of Science ®Google Scholar
• Kohno N, Awaya Y, Oyama T, et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis. 1993;148(3):637–642. doi:10.1164/ajrccm/148.3.637
   PubMed Web of Science ®Google Scholar
• Kobayashi J, Kitamura S. Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis. Chest. 1996;109(5):1276–1282. doi:10.1378/chest.109.5.1276
   PubMed Web of Science ®Google Scholar
• Kubo M, Ihn H, Yamane K, et al. Serum KL-6 in adult patients with polymyositis and dermatomyositis. Rheumatology. 2000;39(6):632–636. doi:10.1093/rheumatology/39.6.632
   PubMed Web of Science ®Google Scholar
• Yamane K, Ihn H, Kubo M, et al. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. J Rheumatol. 2000;27(4):930–934.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Taniguchi H, Kondoh Y, et al. Serum KL-6 in fibrotic NSIP: correlations with physiologic and radiologic parameters. Respir Med. 2010;104(1):127–133. doi:10.1016/j.rmed.2009.08.011
   PubMed Web of Science ®Google Scholar
• Takanashi S, Nishina N, Nakazawa M, Kaneko Y, Takeuchi T. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. Rheumatology. 2019;58(6):1034–1039. doi:10.1093/rheumatology/key420
   PubMed Web of Science ®Google Scholar
• Elhai M, Hoffmann-Vold AM, Avouac J, et al. Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2019;71(6):972–982. doi:10.1002/art.40815
   PubMed Web of Science ®Google Scholar
• Ma H, Lu J, Song Y, Wang H, Yin S. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease. BMC Pulm Med. 2020;20(1):6. doi:10.1186/s12890-019-1043-z
   PubMed Web of Science ®Google Scholar
• Kim HC, Choi KH, Jacob J, Song JW, Kuwana M. Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease. PLoS One. 2020;15(3):e0229997. doi:10.1371/journal.pone.0229997
   PubMed Web of Science ®Google Scholar
• Lee JS, Lee EY, Ha YJ, Kang EH, Lee YJ, Song YW. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res Ther. 2019;21(1):58. doi:10.1186/s13075-019-1835-9
   PubMed Web of Science ®Google Scholar
• Wang J, Zheng P, Huang Z, et al. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features. BMC Pulm Med. 2020;20(1):315. doi:10.1186/s12890-020-01336-y
   PubMed Web of Science ®Google Scholar
• Xue M, Cai C, Zeng Y, et al. Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features. Medicine. 2021;100(4):e24260. doi:10.1097/MD.0000000000024260
   PubMed Web of Science ®Google Scholar
• Kamiya Y, Fujisawa T, Kono M, et al. Prognostic factors for primary Sjogren’s syndrome-associated interstitial lung diseases. Respir Med. 2019;159:105811. doi:10.1016/j.rmed.2019.105811
   PubMed Web of Science ®Google Scholar
• Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun. 2005;338(4):1845–1852. doi:10.1016/j.bbrc.2005.10.144
   PubMed Web of Science ®Google Scholar
• Roca F, Dominique S, Schmidt J, et al. Interstitial lung disease in primary Sjogren’s syndrome. Autoimmun Rev. 2017;16(1):48–54. doi:10.1016/j.autrev.2016.09.017
   PubMed Web of Science ®Google Scholar
• Kampolis CF, Fragkioudaki S, Mavragani CP, Zormpala A, Samakovli A, Moutsopoulos HM. Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjogren’s syndrome. Clin Exp Rheumatol. 2018;36(Suppl 112):94–101.
   PubMedGoogle Scholar
• Elhai M, Avouac J, Allanore Y. Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: where do we stand? Semin Arthritis Rheum. 2020;50(3):480–491. doi:10.1016/j.semarthrit.2020.01.006
   PubMed Web of Science ®Google Scholar
• Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S. Pulmonary manifestations of Sjogren’s syndrome. Eur Respir Rev. 2016;25(140):110–123. doi:10.1183/16000617.0011-2016
   PubMed Web of Science ®Google Scholar
• Chiu YH, Spierings J, de Jong PA, et al. Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases. Respir Med. 2021;187:106579. doi:10.1016/j.rmed.2021.106579
   PubMed Web of Science ®Google Scholar